Management of Budd-Chiari syndrome

Thrombotic occlusion of the hepatic veins leads to liver dysfunction and liver failure requiring liver transplantation in advanced cases. The cause for the occlusion of the hepatic veins is not completely understood. However, several underlying conditions such as polycytemia, factor V Leiden mutatio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Digestive diseases and sciences 2005-03, Vol.50 (3), p.540-546
Hauptverfasser: RUH, Joachim, MALAGO, Massimo, BUSCH, Yasmin, LANG, Hauke, PAUL, Andreas, VERHAGEN, Rüdiger, BROELSCH, Christoph E
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 546
container_issue 3
container_start_page 540
container_title Digestive diseases and sciences
container_volume 50
creator RUH, Joachim
MALAGO, Massimo
BUSCH, Yasmin
LANG, Hauke
PAUL, Andreas
VERHAGEN, Rüdiger
BROELSCH, Christoph E
description Thrombotic occlusion of the hepatic veins leads to liver dysfunction and liver failure requiring liver transplantation in advanced cases. The cause for the occlusion of the hepatic veins is not completely understood. However, several underlying conditions such as polycytemia, factor V Leiden mutation, and protein C and S deficiency are found in these patients. We here report our single-center experience with 18 consecutive patients with Budd-Chiari Syndrome (BCS) who were treated at our institution between August 1992 and June 2003. Twelve patients underwent liver transplantation, three patients received stents into the hepatic veins or vena cava, another patient was treated with TIPSS (transjugular intrahepatic postosystemic stent shunt), and one patient underwent surgical mesocaval shunting. Three patients, among those the patient with TIPSS, were put on anticoagulant therapy and are scheduled for liver transplantation. We outline the indication for an approach tailored to the stage of the disease and the adaption of the procedures with the deterioration of clinical conditions. Surgical aspects and postoperative management with a focus on liver transplantation are outlined. We conclude from our observations that the management of BCS requires an approach that exhausts conservative approaches until clinical conditions deteriorate with respect to portal hypertension or liver function. Conservative management, i.e., interventional and supportive medical therapy, has been used up to 8 years in our series, until the time for liver transplantation is reached. Liver transplantation for BCS had more complications than transplantation for other liver diseases in our series. Therefore, we propose to keep liver function stable using interventional techniques to maintain venous outflow. If venous outflow cannot be interventionally restored and liver function deteriorates or cirrhosis develops during this time course, liver transplantation is the therapy of choice.
doi_str_mv 10.1007/s10620-005-2471-6
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67709598</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67709598</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-2ac3d15dffc959e85105f7c291dab19ce6f7cd369c2dd60bbe1e404d9ce51e063</originalsourceid><addsrcrecordid>eNpdkMtKAzEUhoMotlYfwI0UQXfRcyaTzGSpxRtU3Og6ZHLRKXOpSWfRtzelAwVXJ4d85-fnI-QS4Q4BivuIIDKgAJxmeYFUHJEp8oLRjIvymEwBRXojigk5i3EFALJAcUomyMt0yuSUXL_rTn-71nWbee_nj4O1dPFT61DP47azoW_dOTnxuonuYpwz8vX89Ll4pcuPl7fFw5IaxsWGZtowi9x6bySXruQI3Bcmk2h1hdI4kTbLhDSZtQKqyqHLIbfph6NLbWbkdp-7Dv3v4OJGtXU0rml05_ohKlEUkJLLBF7_A1f9ELrUTWWYMybzHBKEe8iEPsbgvFqHutVhqxDUzp7a21PJntrZU7sGV2PwULXOHi5GXQm4GQEdjW580J2p44ETosy5APYHrRx1WQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>214339440</pqid></control><display><type>article</type><title>Management of Budd-Chiari syndrome</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>RUH, Joachim ; MALAGO, Massimo ; BUSCH, Yasmin ; LANG, Hauke ; PAUL, Andreas ; VERHAGEN, Rüdiger ; BROELSCH, Christoph E</creator><creatorcontrib>RUH, Joachim ; MALAGO, Massimo ; BUSCH, Yasmin ; LANG, Hauke ; PAUL, Andreas ; VERHAGEN, Rüdiger ; BROELSCH, Christoph E</creatorcontrib><description>Thrombotic occlusion of the hepatic veins leads to liver dysfunction and liver failure requiring liver transplantation in advanced cases. The cause for the occlusion of the hepatic veins is not completely understood. However, several underlying conditions such as polycytemia, factor V Leiden mutation, and protein C and S deficiency are found in these patients. We here report our single-center experience with 18 consecutive patients with Budd-Chiari Syndrome (BCS) who were treated at our institution between August 1992 and June 2003. Twelve patients underwent liver transplantation, three patients received stents into the hepatic veins or vena cava, another patient was treated with TIPSS (transjugular intrahepatic postosystemic stent shunt), and one patient underwent surgical mesocaval shunting. Three patients, among those the patient with TIPSS, were put on anticoagulant therapy and are scheduled for liver transplantation. We outline the indication for an approach tailored to the stage of the disease and the adaption of the procedures with the deterioration of clinical conditions. Surgical aspects and postoperative management with a focus on liver transplantation are outlined. We conclude from our observations that the management of BCS requires an approach that exhausts conservative approaches until clinical conditions deteriorate with respect to portal hypertension or liver function. Conservative management, i.e., interventional and supportive medical therapy, has been used up to 8 years in our series, until the time for liver transplantation is reached. Liver transplantation for BCS had more complications than transplantation for other liver diseases in our series. Therefore, we propose to keep liver function stable using interventional techniques to maintain venous outflow. If venous outflow cannot be interventionally restored and liver function deteriorates or cirrhosis develops during this time course, liver transplantation is the therapy of choice.</description><identifier>ISSN: 0163-2116</identifier><identifier>EISSN: 1573-2568</identifier><identifier>DOI: 10.1007/s10620-005-2471-6</identifier><identifier>PMID: 15810639</identifier><identifier>CODEN: DDSCDJ</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Adult ; Anticoagulants - therapeutic use ; Biological and medical sciences ; Budd-Chiari Syndrome - diagnosis ; Budd-Chiari Syndrome - mortality ; Budd-Chiari Syndrome - therapy ; Cohort Studies ; Combined Modality Therapy ; Female ; Follow-Up Studies ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Liver Transplantation ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Male ; Medical sciences ; Middle Aged ; Other diseases. Semiology ; Portasystemic Shunt, Surgical - methods ; Portasystemic Shunt, Transjugular Intrahepatic ; Retrospective Studies ; Risk Assessment ; Severity of Illness Index ; Stents ; Survival Rate ; Treatment Outcome</subject><ispartof>Digestive diseases and sciences, 2005-03, Vol.50 (3), p.540-546</ispartof><rights>2005 INIST-CNRS</rights><rights>Springer Science + Business Media, Inc. 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-2ac3d15dffc959e85105f7c291dab19ce6f7cd369c2dd60bbe1e404d9ce51e063</citedby><cites>FETCH-LOGICAL-c356t-2ac3d15dffc959e85105f7c291dab19ce6f7cd369c2dd60bbe1e404d9ce51e063</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=16684560$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15810639$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>RUH, Joachim</creatorcontrib><creatorcontrib>MALAGO, Massimo</creatorcontrib><creatorcontrib>BUSCH, Yasmin</creatorcontrib><creatorcontrib>LANG, Hauke</creatorcontrib><creatorcontrib>PAUL, Andreas</creatorcontrib><creatorcontrib>VERHAGEN, Rüdiger</creatorcontrib><creatorcontrib>BROELSCH, Christoph E</creatorcontrib><title>Management of Budd-Chiari syndrome</title><title>Digestive diseases and sciences</title><addtitle>Dig Dis Sci</addtitle><description>Thrombotic occlusion of the hepatic veins leads to liver dysfunction and liver failure requiring liver transplantation in advanced cases. The cause for the occlusion of the hepatic veins is not completely understood. However, several underlying conditions such as polycytemia, factor V Leiden mutation, and protein C and S deficiency are found in these patients. We here report our single-center experience with 18 consecutive patients with Budd-Chiari Syndrome (BCS) who were treated at our institution between August 1992 and June 2003. Twelve patients underwent liver transplantation, three patients received stents into the hepatic veins or vena cava, another patient was treated with TIPSS (transjugular intrahepatic postosystemic stent shunt), and one patient underwent surgical mesocaval shunting. Three patients, among those the patient with TIPSS, were put on anticoagulant therapy and are scheduled for liver transplantation. We outline the indication for an approach tailored to the stage of the disease and the adaption of the procedures with the deterioration of clinical conditions. Surgical aspects and postoperative management with a focus on liver transplantation are outlined. We conclude from our observations that the management of BCS requires an approach that exhausts conservative approaches until clinical conditions deteriorate with respect to portal hypertension or liver function. Conservative management, i.e., interventional and supportive medical therapy, has been used up to 8 years in our series, until the time for liver transplantation is reached. Liver transplantation for BCS had more complications than transplantation for other liver diseases in our series. Therefore, we propose to keep liver function stable using interventional techniques to maintain venous outflow. If venous outflow cannot be interventionally restored and liver function deteriorates or cirrhosis develops during this time course, liver transplantation is the therapy of choice.</description><subject>Adult</subject><subject>Anticoagulants - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Budd-Chiari Syndrome - diagnosis</subject><subject>Budd-Chiari Syndrome - mortality</subject><subject>Budd-Chiari Syndrome - therapy</subject><subject>Cohort Studies</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Liver Transplantation</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Other diseases. Semiology</subject><subject>Portasystemic Shunt, Surgical - methods</subject><subject>Portasystemic Shunt, Transjugular Intrahepatic</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>Severity of Illness Index</subject><subject>Stents</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>0163-2116</issn><issn>1573-2568</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkMtKAzEUhoMotlYfwI0UQXfRcyaTzGSpxRtU3Og6ZHLRKXOpSWfRtzelAwVXJ4d85-fnI-QS4Q4BivuIIDKgAJxmeYFUHJEp8oLRjIvymEwBRXojigk5i3EFALJAcUomyMt0yuSUXL_rTn-71nWbee_nj4O1dPFT61DP47azoW_dOTnxuonuYpwz8vX89Ll4pcuPl7fFw5IaxsWGZtowi9x6bySXruQI3Bcmk2h1hdI4kTbLhDSZtQKqyqHLIbfph6NLbWbkdp-7Dv3v4OJGtXU0rml05_ohKlEUkJLLBF7_A1f9ELrUTWWYMybzHBKEe8iEPsbgvFqHutVhqxDUzp7a21PJntrZU7sGV2PwULXOHi5GXQm4GQEdjW580J2p44ETosy5APYHrRx1WQ</recordid><startdate>20050301</startdate><enddate>20050301</enddate><creator>RUH, Joachim</creator><creator>MALAGO, Massimo</creator><creator>BUSCH, Yasmin</creator><creator>LANG, Hauke</creator><creator>PAUL, Andreas</creator><creator>VERHAGEN, Rüdiger</creator><creator>BROELSCH, Christoph E</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20050301</creationdate><title>Management of Budd-Chiari syndrome</title><author>RUH, Joachim ; MALAGO, Massimo ; BUSCH, Yasmin ; LANG, Hauke ; PAUL, Andreas ; VERHAGEN, Rüdiger ; BROELSCH, Christoph E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-2ac3d15dffc959e85105f7c291dab19ce6f7cd369c2dd60bbe1e404d9ce51e063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Anticoagulants - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Budd-Chiari Syndrome - diagnosis</topic><topic>Budd-Chiari Syndrome - mortality</topic><topic>Budd-Chiari Syndrome - therapy</topic><topic>Cohort Studies</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Liver Transplantation</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Other diseases. Semiology</topic><topic>Portasystemic Shunt, Surgical - methods</topic><topic>Portasystemic Shunt, Transjugular Intrahepatic</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>Severity of Illness Index</topic><topic>Stents</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>RUH, Joachim</creatorcontrib><creatorcontrib>MALAGO, Massimo</creatorcontrib><creatorcontrib>BUSCH, Yasmin</creatorcontrib><creatorcontrib>LANG, Hauke</creatorcontrib><creatorcontrib>PAUL, Andreas</creatorcontrib><creatorcontrib>VERHAGEN, Rüdiger</creatorcontrib><creatorcontrib>BROELSCH, Christoph E</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Digestive diseases and sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>RUH, Joachim</au><au>MALAGO, Massimo</au><au>BUSCH, Yasmin</au><au>LANG, Hauke</au><au>PAUL, Andreas</au><au>VERHAGEN, Rüdiger</au><au>BROELSCH, Christoph E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of Budd-Chiari syndrome</atitle><jtitle>Digestive diseases and sciences</jtitle><addtitle>Dig Dis Sci</addtitle><date>2005-03-01</date><risdate>2005</risdate><volume>50</volume><issue>3</issue><spage>540</spage><epage>546</epage><pages>540-546</pages><issn>0163-2116</issn><eissn>1573-2568</eissn><coden>DDSCDJ</coden><abstract>Thrombotic occlusion of the hepatic veins leads to liver dysfunction and liver failure requiring liver transplantation in advanced cases. The cause for the occlusion of the hepatic veins is not completely understood. However, several underlying conditions such as polycytemia, factor V Leiden mutation, and protein C and S deficiency are found in these patients. We here report our single-center experience with 18 consecutive patients with Budd-Chiari Syndrome (BCS) who were treated at our institution between August 1992 and June 2003. Twelve patients underwent liver transplantation, three patients received stents into the hepatic veins or vena cava, another patient was treated with TIPSS (transjugular intrahepatic postosystemic stent shunt), and one patient underwent surgical mesocaval shunting. Three patients, among those the patient with TIPSS, were put on anticoagulant therapy and are scheduled for liver transplantation. We outline the indication for an approach tailored to the stage of the disease and the adaption of the procedures with the deterioration of clinical conditions. Surgical aspects and postoperative management with a focus on liver transplantation are outlined. We conclude from our observations that the management of BCS requires an approach that exhausts conservative approaches until clinical conditions deteriorate with respect to portal hypertension or liver function. Conservative management, i.e., interventional and supportive medical therapy, has been used up to 8 years in our series, until the time for liver transplantation is reached. Liver transplantation for BCS had more complications than transplantation for other liver diseases in our series. Therefore, we propose to keep liver function stable using interventional techniques to maintain venous outflow. If venous outflow cannot be interventionally restored and liver function deteriorates or cirrhosis develops during this time course, liver transplantation is the therapy of choice.</abstract><cop>Heidelberg</cop><pub>Springer</pub><pmid>15810639</pmid><doi>10.1007/s10620-005-2471-6</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0163-2116
ispartof Digestive diseases and sciences, 2005-03, Vol.50 (3), p.540-546
issn 0163-2116
1573-2568
language eng
recordid cdi_proquest_miscellaneous_67709598
source MEDLINE; Springer Nature - Complete Springer Journals
subjects Adult
Anticoagulants - therapeutic use
Biological and medical sciences
Budd-Chiari Syndrome - diagnosis
Budd-Chiari Syndrome - mortality
Budd-Chiari Syndrome - therapy
Cohort Studies
Combined Modality Therapy
Female
Follow-Up Studies
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Liver Transplantation
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Male
Medical sciences
Middle Aged
Other diseases. Semiology
Portasystemic Shunt, Surgical - methods
Portasystemic Shunt, Transjugular Intrahepatic
Retrospective Studies
Risk Assessment
Severity of Illness Index
Stents
Survival Rate
Treatment Outcome
title Management of Budd-Chiari syndrome
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T05%3A17%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20Budd-Chiari%20syndrome&rft.jtitle=Digestive%20diseases%20and%20sciences&rft.au=RUH,%20Joachim&rft.date=2005-03-01&rft.volume=50&rft.issue=3&rft.spage=540&rft.epage=546&rft.pages=540-546&rft.issn=0163-2116&rft.eissn=1573-2568&rft.coden=DDSCDJ&rft_id=info:doi/10.1007/s10620-005-2471-6&rft_dat=%3Cproquest_cross%3E67709598%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=214339440&rft_id=info:pmid/15810639&rfr_iscdi=true